AboBoNT-A + OnaBoNT-A

ApprovedCompleted
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Upper Limb Spasticity

Conditions

Upper Limb Spasticity

Trial Timeline

Jun 23, 2021 → Aug 26, 2025

About AboBoNT-A + OnaBoNT-A

AboBoNT-A + OnaBoNT-A is a approved stage product being developed by Ipsen for Upper Limb Spasticity. The current trial status is completed. This product is registered under clinical trial identifier NCT04936542. Target conditions include Upper Limb Spasticity.

What happened to similar drugs?

5 of 14 similar drugs in Upper Limb Spasticity were approved

Approved (5) Terminated (1) Active (9)
Remimazolam TosilateJiangsu Hengrui MedicineApproved
BOTOXAbbVieApproved
Montelukast + PlaceboMerckApproved
Diclofenac gelNovartisApproved
🔄Muntelukast + PlaceboMerckPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04936542ApprovedCompleted

Competing Products

20 competing products in Upper Limb Spasticity

See all competitors